Clinical trials: Pulmonary Hypertension Due to Left Heart Disease
Heart Diseases, Hypertension, Pulmonary
Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery
Endothelin-1 is a powerful substance that may be involved in causing hemodynamic instability (problems related to unstable blood pressure) during and after open heart surgery.
- Trial name
- NCT00458276
- Testing
- tezosentan
- Where
- 33 sites in United States, Austria and 12 more
- Volunteers
- 274 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pulmonary Hypertension Due to Left Heart Disease
Registry for Pulmonary Hypertension Due to Left Heart Disease in China
Left heart disease is the main cause of pulmonary hypertension. With the advent of the aging society, chronic heart failure has become a global public health problem.
- Trial name
- NCT02164526
- Testing
- Routine therapy
- Where
- 2 sites in China
- Volunteers
- 520 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Heart Failure With Reduced Ejection Fraction, Pulmonary Hypertension
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Pulmonary Hypertension, Right Heart Failure Due to Left Heart Failure
- Trial name
- HALT-RHF (NCT06299436)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins University
Pulmonary Hypertension Due to Left Heart Disease
A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)
Researchers are looking for a better way to treat people who have pulmonary hypertension (PH) due to left heart disease. PH due to left heart disease is a condition of high blood pressure in the vessels of the lungs caused by…
- Trial name
- NCT06048120
- Testing
- BAY2701250 IV, BAY2701250 SC
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bayer
Pulmonary Hypertension (PH) Due to Left Heart Disease
TReatment of Pulmonary Hypertension Group II Study
The objective of this study is to assess the safety and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation in group II PH patients through change in clinical parameters including hemodynamics…
- Trial name
- TROPHY-II (NCT03611270)
- Testing
- Pulmonary Denervation
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- SoniVie Inc.
Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension (PH)
Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.
Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin.
- Conditions
- Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension (PH), Heart Failure
- Trial name
- BREATHE-PH (NCT07537517)
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Pulmonary Hypertension Due to Left Heart Disease
Telemonitoring to Treat Group 2 Pulmonary Hypertension
This study aims to decrease elevated pressure in the lungs of patients with pulmonary hypertension from left heart with elevated pulmonary vascular resistance by utilizing aggressive fluid management with ReDS Pro System and…
- Trial name
- RECAPTURE (NCT04882774)
- Testing
- Treprostinil Diolamine
- Where
- 3 sites in United States
- Sponsor
- Mardi Gomberg -Maitland MD, MSc
Pulmonary Hypertension Due to Left Heart Disease
Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension
The investigator compared difference between inhaled and intravenous milirinone in patiens with severe pulmonary hypertension undergoing cardiac surgery
- Trial name
- NCT04484675
- Testing
- Milrinone inhalation, Milrinone infusion
- Where
- Egypt
- Volunteers
- 38 people
- Sponsor
- Zagazig University
Pulmonary Hypertension
The Role of Endothelin in Pulmonary Hypertension
The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.
- Trial name
- NCT00759408
- Testing
- BQ-123
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Pulmonary Hypertension Biorepository and Registry
Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary
- Trial name
- PHBR (NCT04808596)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Kansas Medical Center
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- The PULSE-LHD (NCT07214376)
- Testing
- Pulmonary Artery Denervation (PADN)
- Where
- 18 sites in United States, China
- Volunteers
- 750 people
- Sponsor
- Pulnovo Medical, Inc.
Pulmonary Hypertension Due to Left Heart Disease, Heart Failure With Preserved Ejection Fraction
Training in HFpEF-PH
Exercise interventions alone or as a component of a comprehensive cardiac rehabilitation program for patients with heart failure (HFrEF and HFpEF) have already shown to reduce the risk of hospitalisations due to HF and improved…
- Trial name
- TRAIN HFpEF (NCT05464238)
- Testing
- Exercise rehabilitation, Standard treatment
- Where
- 2 sites in Germany, Lithuania
- Volunteers
- 90 people
- Sponsor
- Heidelberg University
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure
It's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF) patients diagnosed with pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- PADN-HF-PH (NCT05824923)
- Testing
- Pulmonary arterial denervation, Guideline-directed medical therapy (GDMT) for heart failure
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Pulnovo Medical (Wuxi) Co., Ltd.
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca